Answers are grounded in this paper and cite their sources.
INSTIs seem to have no impact on hepatic steatosis, even though they were associated with a significant increase in BMI. This might be explained by the direct effect of a dolutegravir-containing regimen and/or by the "return-to-health effect" observed with ART initiation. Furthermore, INSTIs were associated with a reduction in risk of liver fibrosis in ART-naïve persons with HIV, possibly due to their effect on viral suppression.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: